Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: A pilot study by Britten, Carolyn D et al.
RESEARCH ARTICLE Open Access
Transarterial chemoembolization plus or minus
intravenous bevacizumab in the treatment of
hepatocellular cancer: A pilot study
Carolyn D Britten
1*, Antoinette S Gomes
2, Zev A Wainberg
1, David Elashoff
3, Rafael Amado
1, Yan Xin
4,
Ronald W Busuttil
5, Dennis J Slamon
1 and Richard S Finn
1
Abstract
Background: Stimulation of vascular endothelial growth factor (VEGF) has been observed following transarterial
chemoembolization (TACE) in hepatocellular cancer (HCC) and may contribute to tumor regrowth. This pilot study
examined whether intravenous (IV) bevacizumab, a monoclonal antibody against VEGF, could inhibit neovessel
formation after TACE.
Methods: 30 subjects with HCC undergoing TACE at a single academic institution were randomized with a computer-
generated allocation in a one to one ratio to either bevacizumab at a dose of 10 mg/kg IV every 14 days beginning 1
week prior to TACE (TACE-BEV arm) or observation (TACE-O arm). Angiography was performed with TACE at day 8, and
again at weeks 10 and 14. Repeat TACE was performed at week 14 if indicated. TACE-BEV subjects were allowed to
continue bevacizumab beyond week 16. TACE-O subjects were allowed to cross-over to bevacizumab at week 16 in the
setting of progressive disease. The main outcome measure was a comparison of neovessel formation by serial
angiography. Secondary outcome measures were progression free survival (PFS) at 16 weeks, overall survival (OS),
bevacizumab safety, and an analysis of VEGF levels before and after TACE with and without bevacizumab.
Results: Among the 30 subjects enrolled, 9 of 15 randomized to the TACE-O arm and 14 of 15 randomized to the
TACE-BEV arm completed all 3 angiograms. At week 14, 3 of 9 (33%) TACE-O subjects and 2 of 14 (14%) TACE-BEV
subjects demonstrated neovascularity. The PFS at 16 weeks was 0.19 in the TACE-O arm and 0.79 in the TACE-BEV
arm (p = 0.021). The median OS was 61 months in the TACE-O arm and 49 months in the TACE-BEV arm (p =
0.21). No life-threatening bevacizumab-related toxicities were observed. There were no substantial differences in
bevacizumab pharmacokinetics compared to historical controls. Bevacizumab attenuated the increase in VEGF
observed post-TACE.
Conclusions: IV bevacizumab was well tolerated in selected HCC subjects undergoing TACE, and appeared to
diminish neovessel formation at week 14.
Trial registration: ClinicalTrials.gov NCT00049322.
Background
Hepatocellular cancer (HCC) is a global health concern,
with an incidence exceeding 500,000 new cases per year
worldwide [1]. In the United States, HCC is one of the
few cancers with rising rates of incidence and mortality
[2]. This increasing incidence has been directly linked to
hepatitis C, and indirectly linked, through studies in
obesity and diabetes, to non-alcoholic steatohepatitis
(NASH) [3-5].
The management of hepatocellular cancer (HCC) is
dictated by the degree of underlying liver dysfunction,
the burden of malignancy, and the patient’s performance
status [6]. Within this framework, patients are stratified
into treatment groups, including resection, percutaneous
ablation, transarterial chemoembolization (TACE),
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any medium, provided the original work is properly cited.orthotopic liver transplantation (OLT), systemic therapy,
and/or supportive care. TACE is generally employed in
the treatment of large (> 3 cm) or multifocal HCC con-
fined to the liver, in the context of preserved liver func-
tion [6]. Although TACE is a palliative procedure by
itself, TACE may be used to control disease in patients
awaiting curative OLT.
TACE takes therapeutic advantage of the liver’sd u a l
blood supply: hepatocellular cancer cells are preferen-
tially supplied by branches of the hepatic artery, whereas
hepatocytes are preferentially supplied by branches of
the portal vein [6]. By infusing chemotherapeutic agents
directly into vessels supplying the tumor, and subse-
quently obstructing these vessels with an embolization
material, the HCC receives prolonged exposure to the
chemotherapeutic agent, and is deprived of its’ blood
supply. This technique has demonstrated its ability to
improve overall survival compared to supportive care in
a meta-analysis [7], and in randomized phase III clinical
trials [8,9]. Ultimately, however, TACE fails due to
incomplete embolization, partial recanalization, and/or
induction of neovascularization [10].
Vascular endothelial growth factor (VEGF) is a potent
regulator of neovascularization that appears to play a
role in HCC [11]. Serum VEGF levels are higher in
patients with HCC than in patients with benign liver
lesions or healthy controls [12,13]. Also, higher serum
or plasma VEGF levels predict clinicopathologic features
of HCC, including increased tumor size, presence of dis-
tant metastases and/or vascular invasion, and advanced
stage [12-14]. Patients with higher pre-operative serum
VEGF levels have decreased disease-free and overall sur-
vival [13,15], and patients with higher pre-procedure
VEGF levels are less likely to respond to TACE [12,16].
Finally, TACE appears to upregulate VEGF through an
induction of tumor anoxia and ischemia [10,12,17]. This
evidence supports the investigation of anti-VEGF ther-
apy in the treatment of HCC.
Given the role of VEGF in HCC, and the changes in
VEGF associated with TACE, this pilot study was
designed to test the hypothesis that therapy directed
against VEGF may improve upon the results observed
with TACE alone. Bevacizumab, a humanized monoclo-
nal antibody against VEGF was chosen over one of the
multi-targeted anti-angiogenic agents because bevacizu-
mab could more directly test the VEGF hypothesis.
Also, in an orthotopic HCC Hep3B model, bevacizumab
significantly decreased tumor microvessel density,
decreased human serum a-fetoprotein (AFP), and pro-
longed the time to progression in treatment mice com-
pared to control mice [18]. In this investigator-initiated
pilot study, patients who were scheduled to undergo
TACE were randomized to either observation (TACE-
O) or intravenous bevacizumab (TACE-BEV). All
patients underwent sequential angiograms, providing a
unique opportunity to study neovascularity in real time.
The principal objective was to compare neovessel for-
mation at 10 and 14 weeks in patients treated with
TACE plus or minus intravenous bevacizumab. The sec-
ondary objectives were to: i) assess progression free sur-
vival (PFS) at 16 weeks; ii) determine overall survival
(OS); iii) describe the toxicities of bevacizumab in liver
disease; iv) evaluate the pharmacokinetics (PK) of beva-
cizumab in liver disease; and v) measure VEGF before
and after TACE with and without bevacizumab.
Methods
Patient selection
Eligible subjects at a single academic institution had
HCC by virtue of either: i) the European Association for
the Study of the Liver (EASL) diagnostic imaging criteria
[19]; or ii) biopsy. All subjects were clinical candidates
for TACE with at least one lesion ≥ 3c ma n dn ol e s i o n
≥ 15 cm, and no more than three lesions total. Tumor
location had to permit embolization of all tumor
nodules on initial TACE. Subjects awaiting OLT were
eligible if their model for end-stage liver disease
(MELD) priority score was < 28 points at entry. The
MELD score cutoff was based on a median MELD score
of 30 at the time of transplant at our institution during
the period that the study was conducted. This allowed
subjects to complete the three scheduled angiograms
before being withdrawn from study.
Subjects were excluded if they had Child’s class C liver
dysfunction, Eastern Cooperative Oncology Group
(ECOG) Performance Status (PS) >2, bilirubin >2.5 mg/
dL, INR > 1.5, extrahepatic disease, or thrombosis of the
main portal vein. Subjects were excluded if they demon-
strated contraindications to bevacizumab. Initially, sub-
jects were excluded if they had platelets < 100,000/μL.
After the first three subjects enrolled in the TACE-BEV
arm completed week 10 without significant bleeding
(defined as bleeding requiring transfusion), additional
subjects were excluded if they had platelets < 75,000/μL.
After safety was confirmed using the 75,000/μLp l a t e l e t
cut-off, the protocol was amended in consultation with
the Food and Drug Administration (FDA) to exclude
subjects with platelets < 60,000/μL, in an effort to
improve accrual. The protocol was approved by the
Medical Institutional Review Board at the University of
California, Los Angeles. Written informed consent was
obtained and the study was conducted according to fed-
eral and institutional guidelines, observing the standards
set by the Helsinki Declaration.
Study design and treatment procedures
The study design is depicted in Figure 1. A one to one
randomization was performed with a computer-
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TACE-O or TACE-BEV.
Hepatic angiograms were scheduled at day 8, week 10,
and week 14. The day 8 procedure included TACE of all
lesions. The week 10 and 14 angiograms were per-
formed to assess tumor vascularity. Two observation
points were chosen because it was unknown how long it
would take to develop a treatment effect, and 10 and 14
weeks were specifically selected to approximate the 2 to
3 months separating the first and second scheduled
TACE procedures in previous clinical trials (8,9). TACE
was not performed during the week 10 angiogram, justi-
fied by the opportunity for TACE at week 14. At week
14, a second TACE was performed if: i) a previously
embolized feeding vessel had recanalized; or ii) there
was residual tumor blush in a treated area, and a feeding
vessel was visualized; or iii) new lesions had developed
that were amenable to TACE.
TACE was performed using doxorubicin 25 mg/m
2
(emulsified with lipiodol, 10-12 mL), cisplatin 50 mg/
m
2, and mitomycin-C 5 mg/m
2, with Embosphere
®
microspheres (Biosphere Medical, Rockland, MA). Che-
motherapy and the embolic agent were administered
through the hepatic artery to segmental and/or subseg-
mental branches feeding the tumor. Stump occlusion of
segmental or subsegmental feeding branches was per-
formed with microfibrillar collagen (Avitene, Davol, Inc.,
Cranston RI) as needed to achieve stasis. Following
TACE, subjects were admitted to the hospital for at
least 24 h, where they received hydration, pain control,
and antiemetics as needed. Subjects also received metro-
nidazole and ciprofloxacin for 7 days after TACE.
Subjects randomized to TACE-BEV received bevacizu-
mab 10 mg/kg intravenously (IV) on day 1, one week
prior to the first TACE. Post-TACE, bevacizumab
administration resumed at 10 mg/kg every 2 weeks, as
long as serum transaminases had returned to pre-TACE
levels, or within normal range. Subjects receiving bevaci-
zumab with no signs of progressive disease were allowed
to continue bevacizumab therapy until: i) they experi-
enced unacceptable toxicity; or ii) they developed tumor
progression (as defined below); or iii) their MELD score
increased to > 28 points; or iv) they requested disconti-
nuation of drug.
Subjects randomized to TACE-O were eligible to
cross-over to bevacizumab at week 16 if they had evi-
dence of progressive disease. Subjects who crossed over
were required to meet the original eligibility criteria,
and the criteria for bevacizumab administration status
post TACE, as outlined above.
Pretreatment and follow-up studies
All subjects underwent baseline procedures including a
history and physical, 12-lead electrocardiogram, and
Days
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Figure 1 Study design.
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phy scan (CT) and/or contrast enhanced magnetic reso-
nance imaging scan (MRI) of the liver within 4 weeks of
starting protocol treatment. Additional staging investiga-
tions were performed at the discretion of the investiga-
tor. Subjects with documented grade III varices, or a
history of upper gastrointestinal bleeding, were required
to undergo endoscopic evaluation prior to study treat-
ment. Within 2 weeks of starting protocol treatment, a
physical exam, complete blood count (CBC), compre-
hensive metabolic panel (CMP), international normal-
ized ratio (INR), urinalysis, and AFP were performed.
The first 16 weeks constituted the core treatment per-
iod. CBCs and CMPs were obtained daily for 3 days
post-TACE, 1 week post-TACE, 2 weeks post-TACE,
and every 4 weeks thereafter. This CBC and CMP sche-
dule was repeated after a second TACE. An INR was
obtained on day 3 post-TACE, then 3 weeks post-
TACE, and every 4 weeks thereafter. This INR schedule
was repeated after a second TACE. AFP was obtained
every 2 weeks for the first 16 weeks, then every 4 weeks
thereafter. Urinalysis or urine dipstick to screen for pro-
teinuria was performed every 2 weeks. Physical exams
were performed within 2 weeks prior to all angiograms
and within 2 weeks following all angiograms. Toxicities
were graded according to the National Cancer Institute
common toxicity criteria (CTC), version 3.0. Follow-up
CT or MRI was performed at weeks 8 and 16.
Subjects who received bevacizumab after week 16
were evaluated at least monthly with a physical exam,
CBC, CMP, INR, and AFP. Urinalysis or urine dipstick
was performed every 2 weeks. These safety evaluations
were also performed at 30 and 60 days after the last
dose of bevacizumab. CT or MRI for disease assessment
was performed every 8 weeks while on bevacizumab.
Subjects who completed the 16 week core phase plus
or minus the bevacizumab continuation phase were fol-
lowed per institutional practice. All subjects were
assessed for survival every 3 months.
Efficacy
Angiograms were assessed for changes in vascularity
using the following parameters: 1) neovessel formation;
2) recanalization; 3) development of collaterals; and 4)
number of vessels. All changes in vascularity were
assessed with the catheter in the common hepatic artery,
to allow standardized visualization. Neovessels, defined
as fine vessels with disordered arborization patterns,
were scored at weeks 10 and week 14 as follows: 0, no
evidence of neovessel formation; 1+, some evidence of
neovessel formation; 2+, obvious vessel formation (small
vessels); and 3+, obvious vessel formation (small and
large vessels). Recanalization was defined as the restora-
tion of flow in a previously occluded vessel. Collateral
vessels were characterized as small well formed vessels
communicating between non-embolized and embolized
vessels. The number of vessels was determined retrospec-
tively in an unblinded fashion at the end of the study for
all subjects who completed 2 or more angiograms by the
trial interventional radiologist. This angiographic vessel
count was performed using a single field measuring 2.43
cm in diameter (the size of an American quarter) at the
site with the highest tumor vessel density. Although the
arteriograms were obtained in several projections, all
images were graded in anteroposterior projection. Accu-
rate comparisons between studies and reproduction of
magnification factors were achieved by performing the
series of arteriograms in each individual subject with the
same field size, object film distance, external fiducial
marker, and contrast injection parameters as on their
first TACE arteriogram. Vessel counts at 10 and 14
weeks were expressed as percent change from baseline.
Vessel counts were compared between groups using the
Wilcoxon rank sum test.
Cross-sectional imaging was considered along with
angiography when assessing disease progression. Progres-
sive disease was defined as any one of the following: an
increase in the sum of the bidimensional products of all
known disease by at least 25% by cross-sectional imaging,
an increase in enhancement of a previously treated lesion
by cross-sectional imaging, the appearance of a new
lesion, or evidence of neovascularization by angiography
at week 14. The angiographic demonstration of recanali-
zation and/or the development of collaterals without
neovascularization were not considered progressive dis-
ease. An objective response rate by cross-sectional ima-
ging was not determined because most subjects on this
investigator-initiated study were evaluated by CT, and
lipiodol obscured tumor measurements by CT.
Progression free survival (PFS) at 16 weeks (end of the
core phase) and overall survival (OS) were estimated by
the Kaplan-Meier method, using JMP 6 statistical soft-
ware (SAS institute, Cary, NC). The PFS times were
censored based on the minimum time of four possible
events: 1) last disease assessment; 2) orthotopic liver
transplant; 3) second TACE if performed in the absence
of progressive disease (e.g. embolization of a recanalized
vessel without neovessel formation); 4) administration of
a test dose of chemoembolization material, per institu-
tional practice. OS was calculated based on intention to
treat, and cross-over subjects were kept in the observa-
tion arm for the purpose of calculating OS. PFS and OS
were compared between groups using log-rank tests.
Bevacizumab pharmacokinetics
Trough and peak blood samples were drawn from sub-
jects randomized to the TACE-BEV arm for infusions
one through five, and seven. Additional samples were
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h after chemoembolization. Bevacizumab serum concen-
trations were determined by an enzyme-linked immuno-
sorbent assay (ELISA) with a minimum quantifiable
concentration (MQC) in neat serum of 0.078 μg/mL
[20]. Bevacizumab concentration data was characterized
by descriptive statistics at each time-point, with data
described as means and 95% confidence intervals. To
assess the difference of bevacizumab PK between the
HCC subjects on this study and other oncology subjects,
predicted concentrations for 500 patients were simulated
using a population PK model of bevacizumab estab-
lished on data from eight Phase I/II/III clinical trials (on
file at Genentech). In this population PK model, signifi-
cant PK covariates include weight, gender, and serum
albumin on clearance (CL) and volume of distribution
in the central compartment (V1); total protein on clear-
ance; and baseline tumor burden on V1. Mean concen-
trations and associated 95% confidence intervals were
calculated from these simulations and compared to the
study subjects. These simulations were performed in
NONMEM version VI beta, level 1.0 (LLC, Globomax,
Ellicott City, MD).
Serum VEGF levels
Blood samples were obtained at the following time
points: immediately prior to TACE; 1, 24, 48, and 72
hours after TACE; and 7, 15, and 21 days after TACE.
VEGF-A was measured using an ELISA kit specific for
human VEGF (R&D Systems, Minneapolis, MN, USA).
Data was analyzed as the average for each timepoint
and presented as fold-change from baseline. This was
done for all subjects in the observation and bevacizumab
arms that had at least one sample available for analysis.
A one-sided t-test was performed for each timepoint.
Results
Study population
Between August 2003 and October 2008, 54 subjects
were screened and 30 subjects were randomly assigned,
as illustrated in Figure 2. Subject characteristics are out-
lined in Table 1.
Angiogram findings
As demonstrated in Figure 2, three TACE-O subjects
withdrew prior to completing study procedures due to
the volume of disease: one before and two after the first
TACE. An additional three TACE-O subjects withdrew
at their own request before completing all three angio-
grams. In contrast, only one TACE-BEV subject was
withdrawn prior to study completion, due to liver dys-
function experienced after day 8 TACE.
Regarding the primary endpoint of neovessel formation
at weeks 10 and 14, all angiograms were reviewed in real
time, with decision for further treatment based on real
time assessments. At week 10, 4 of 11 (36%) TACE-O and
4 of 14 (29%) TACE-BEV subjects demonstrated neovascu-
larity. At week 14, 3 of 9 (33%) TACE-O and 2 of 14 (14%)
TACE-BEV subjects demonstrated neovascularity. Of note,
the TACE-BEV subject with 3+ neovascularity at week 14
had neovessels arising from a persistent vessel supplying
the tumor that had not been treated during the first
TACE. Figure 3 depicts serial angiograms demonstrating
neovascularity from a subject on the observation arm.
Other angiographic findings included collateralization
and recanalization. Collateralization was present in 3 of
11 (27%) TACE-O subjects and 3 of 14 (21%) TACE-
BEV subjects at week 10, and in 1 of 9 (11%) TACE-O
subjects and 2 of 14 (14%) TACE-BEV subjects at week
14. Recanalization was present in 3 of 11 (27%) TACE-
Os u b j e c t sa n d3o f1 4( 2 1 % )T A C E - B E Vs u b j e c t sa t
week 10, and in 3 of 9 (33%) TACE-O subjects and 4 of
14 (29%) of TACE-BEV subjects at week 14. All subjects
with recanalization and/or collateralization at week 14
underwent TACE with the exception of one TACE-BEV
subject, who had recanalization without active tumor
confirmed by a lack of ethiodol uptake.
I nt o t a l ,4o f9( 4 4 % )T A C E - Os u b j e c t sa n d6o f1 5
(40%) TACE-BEV subjects underwent TACE at week
14. Among the 6 TACE-BEV subjects undergoing TACE
at week 14 were two subjects with persistent vessels
missed during the first TACE, one subject with recanali-
zation, one subject with recanalization and collateraliza-
tion, one subject with collateralization and neovessel
formation, and one subject without evidence of active
tumor who received a test dose of chemoembolization
material in the vessel stump.
In an attempt to quantify the angiographic findings, a
vessel count was performed in all subjects undergoing
more than one angiogram, with week 10 and week 14
results compared to baseline. At week 10, the mean (±
standard deviation) percent change from baseline was
-63.4 ± 57.7% for the TACE-O arm, and -60.4 ± 31.2%
for the TACE-BEV arm, whereas at week 14, the values
were -56.5 ± 54.6% and -61.1 ± 23.3%, respectively.
There was no significant difference between the treat-
ment groups by this measure.
Survival and follow-up
The PFS at 16 weeks was 0.19 in the TACE-O arm and
0.79 in the TACE-BEV arm (p = 0.021), as depicted in Fig-
ure 4. The median OS was 61 months in the TACE-O arm
and 49 months in the TACE-BEV arm (p = 0.21), depicted
in Figure 5. The OS data is based on an intent-to-treat
analysis, independent of cross-over status at week 16.
Among the 12 subjects known to have died, ten suc-
cumbed to hepatocellular cancer and two (one in each
arm) succumbed to liver failure.
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Page 5 of 13Once withdrawn from study, subjects received treatment
per institutional practice, including local modality therapy
for recurrent disease (TACE and/or radiofrequency abla-
tion), OLT, and chemotherapy or sorafenib (beginning in
2007) for advanced disease. 12 subjects (4 observation and
8 bevacizumab) were transplanted, with a median time
from first study TACE to OLT of 11.3 (range, 3.5 to 18.1)
months. Among the transplanted subjects, 10 (8 bevacizu-
mab and 2 cross-over) received bevacizumab during the
study, with a median time from the last dose of bevacizu-
mab to OLT of 8.0 (range, 0.3 to 17.4) months.
Safety
The most common treatment-related toxicities experi-
enced during the first 16 weeks by the 29 subjects who
received study treatment are listed by treatment arm
and maximum CTC grade in Table 2. As expected, all
subjects experienced elevated transaminases, and many
experienced pain, pyrexia, nausea/vomiting, and fatigue.
One TACE-BEV subject developed grade 4 hyperbiliru-
b i n e m i aa f t e rd a y8T A C E ,a n dw a sw i t h d r a w nf r o m
study for liver dysfunction, having received only one
dose of bevacizumab. This subject was subsequently
found to have spontaneous bacterial peritonitis, possibly
related to a paracentesis performed just prior to study
enrollment. With treatment, the liver dysfunction
improved, and he was successfully re-treated with TACE
off study several months later. There were no other
events of severe liver dysfunction. The only clinically
significant hemorrhage during the first 16 weeks
Assessed for Eligibility
(n=54)
Random Assignment
(n=30)
TACE-OBS
(n=15)
TACE-BEV
(n=15)
Completed 1st angiogram   (n=14)
Withdrawn due to disease burden (n=1) Completed 1st angiogram     (n=15)
Completed 2nd angiogram    (n=11)
Withdrawn due to disease burden  (n=2)
Refused 2nd angiogram   (n=1)
Completed 3rd angiogram     (n=9)
Refused 3rd angiogram     (n=2)
Completed 2nd angiogram    (n=14)
Withdrawn due to adverse event  (n=1)
Completed 3rd angiogram     (n=14)
Excluded   (n=24)
Did not meet eligibility (n=13)
Withdrew consent (n=6)
Other   (n=5)
Figure 2 Disposition of subjects.
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Page 6 of 13occurred in a TACE-O subject who developed a grade 3
variceal bleed during week 9. Following banding and
transfusion, she was able to complete the week 10
angiogram without incident.
Table 2 lists three events of grade 3 hypertension in
each of the two treatment arms. In general, TACE-BEV
subjects had sustained hypertension requiring ongoing
treatment, whereas TACE-O subjects had transient
hypertension during and/or immediately following
TACE.
Taking the core (weeks 1 to 16) and continuation
(beyond 16 weeks) phases together, a total of 19 subjects
(15 TACE-BEV and 4 cross-over) received bevacizumab
for a median of 4.7 months (range, 0.03 to 11.6 months).
Bevacizumab-related toxicities included controllable
grade 3 hypertension in 4 subjects, grade 2 to 3 protei-
nuria in 7 subjects, and grade 1 epistaxis in 9 subjects.
Three TACE-BEV subjects experienced gastrointestinal
bleeding during the continuation phase: one subject
with a prior history of varices experienced grade 3 vari-
ceal bleeding within 1 week after withdrawing from
study; another subject experienced grade 2 bleeding
from portal hypertensive gastropathy after nearly 11
months of bevacizumab and was subsequently with-
drawn from study; and a third subject experienced grade
3 bleeding secondary to gastric ulcers within 1 month
after withdrawing from study. Reasons for discontinuing
bevacizumab included bevacizumab-related toxicities (5
subjects), progressive disease (3 subjects), subject with-
drawal (3 subjects), OLT evaluation and/or treatment (3
subjects), progressive thrombocytopenia (2 subjects),
acute liver dysfunction after TACE (1 subject), or a
combination of factors listed above (2 subjects).
Pharmacokinetics
The descriptive statistics for the observed bevacizumab
concentrations and the corresponding predicted concen-
trations from the population simulations are summar-
ized in Table 3 for each time-point. Mean observed
bevacizumab concentrations were generally less than
those predicted from simulations with overlapping 95%-
confidence intervals at each of the assessed time points.
In addition, the clearance of bevacizumab in this study
(mean 12.6 mL/h, ranging from 7.98 to 18.3 mL/h) was
comparable to the clearance in general oncology
patients (mean 9.75 mL/h, ranging from 3.05 to 23.1
mL/h). These data suggest that there are no substantial
differences in bevacizumab PK between HCC subjects
undergoing TACE and other oncology patients. How-
ever, this observation is limited by the small number of
subjects enrolled on the bevacizumab arm (n = 15).
Serum VEGF levels
The effects of TACE on serum VEGF levels in the pre-
sence and absence of VEGF blockade with bevacizumab
are shown in Figure 6. The results are depicted as fold-
change from baseline for the TACE-O and TACE-BEV
arms. VEGF levels increased after TACE in both arms,
however, the fold-change was higher in the TACE-O
arm.
Table 1 Subject Characteristics
Characteristic Number of Subjects
TACE-O TACE-BEV
Total 15 15
Median Age (Range) [58 (49-75)] [61 (50-79)]
Gender
Male 12 13
Female 3 2
ECOG Performance Status
01 3 1 1
12 4
Child-Pugh Class
A1 5 1 3
B0 2
Underlying Liver Disease
a,b
Hepatitis B 2 4
Hepatitis C 9 7
Ethanol-Related 4 1
Cryptogenic 3 3
Hemachromatosis 0 1
Median (Range) Baseline Labs
AFP, ng/mL [14.9 (1.8-
42,550)]
[360 (1.7-
9,097)]
Total Bilirubin, mg/dL [0.9 (0.6-1.4)] [1.1 (0.5-1.7)]
Albumin, mg/dL [4 (2.9-4.4)] [3.7 (2.8-4.4)]
Tumor Characteristics
Mean Tumor Burden
c,c m( ±
SD)
[7.4 (± 2.9)] [6.5 (± 2.0)]
Multifocal Tumor 4 4
Vascular Invasion 1 0
BCLC Stage
A3 1
B1 0 1 0
C
d 24
Previous Anti-Cancer Therapy
Resection Alone 1 0
Resection and TACE 0 1
None 14 14
a On the TACE-O arm, 2 subjects had hepatitis C and ethanol-related disease,
and 1 subject had hepatitis B and C co-infection.
b On the TACE-BEV arm, 1 subject had hepatitis C and hemachromatosis.
c Tumor burden defined as the sum of the longest unidimensional
measurements.
d All subjects with BCLC stage C disease were characterized as stage C due to
an ECOG PS of 1.
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Page 7 of 13Discussion and conclusion
This is the first clinical trial of a systemic anti-angio-
genic agent used in combination with TACE. At the
time that this investigator-initiated pilot trial was
initiated in 2003, systemic anti-angiogenic agents were
unproven in HCC. Subsequent to the initiation of this
study, a molecularly-targeted approach for the treatment
of advanced HCC was validated by the SHARP trial,
which demonstrated an improvement in overall survival
with sorafenib compared to placebo [21]. However, the
use of molecularly-targeted agents in advanced disease
may not take full advantage of the potential activity of
this class of agents. Anti-angiogenic agents are now
being tested in large multi-institutional phase III trials
for subjects with early stage HCC, as an adjunct to
T A C E ,R F A ,a n dr e s e c t i o n .The results of this pilot
a b c
Figure 3 Serial angiograms from a subject on the observation arm demonstrating neovascularity: a) pre-TACE angiogram on Day 8
demonstrating tumor blush; b) post-TACE angiogram on Day 8 demonstrating successful embolization of vessels supplying the
tumor; and c) Week 10 angiogram demonstrating 2+ neovascularity and recanalization.
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Figure 4 Kaplan-Meier plot for progression free survival (PFS). The PFS at 16 weeks was 0.79 in the TACE-BEV arm (solid line) and 0.19 in
the TACE-O arm (dashed line), with a p-value of 0.021
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Figure 5 Kaplan-Meier plot for overall survival (OS). The median OS was 49 months in the TACE-BEV arm (solid line) and 61 months in the
TACE-O arm (dashed line), with a p-value of 0.21
Table 2 Most Common Treatment-Related Toxicities Experienced During First 16 Weeks
Toxicity Number of Subjects by Maximum CTC Grade Total
TACE-BEV (N = 15) TACE-O (N = 14)
Grade 1-2 Grade 3-4 Grade 1-2 Grade 3-4
Anemia 3 0 5 1 9
Anorexia 5 0 4 0 9
Bleeding 8 0 0 1 9
Constipation 4 0 3 0 7
Electrolyte Abnormalities 5 4 8 1 18
Elevated Alkaline Phosphatase 4 0 3 0 7
Elevated Transaminases 1 14 3 11 29
Fatigue 9 0 8 0 17
Hyperbilirubinemia 6 2 7 0 15
Hypertension 3 3 1 3 10
Hypoalbuminemia 5 0 7 0 12
Nausea and/or Vomiting 6 0 9 0 15
Pain 9 2 12 1 24
Proteinuria 7 1 1 0 9
Pyrexia 8 0 7 0 15
Thrombocytopenia 4 3 10 0 17
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Page 9 of 13study of TACE plus or minus bevacizumab demonstrate
that anti-angiogenic agents are a tolerable adjunct to
TACE, and set the stage for larger clinical trials examin-
ing this approach.
TACE in HCC provides a unique opportunity to study
neovascularity in real time, because angiograms are per-
formed as part of the therapeutic procedure. In this
study, angiograms were used qualitatively to determine
neovascularity on a 0 to 3+ scale at 10 and 14 weeks
after TACE, and with this technique, there was a trend
towards decreased neovessel formation in subjects who
r e c e i v e db e v a c i z u m a bc o m p a r e dt ot h o s ew h od i dn o t .
In contrast, bevacizumab did not protect against recana-
lization, perhaps because recanalization represents a
mechanical failure of the embolization material rather
than a response to tumor hypoxia. In addition to the
qualitative analysis of neovessel formation, tumor blood
supply was quantified by measuring blood vessel density
in a representative field on the angiogram, much like
microvessel density is assessed by immunohistochemisty
in tumor biopsies. There was no significant difference in
the angiographic blood vessel density between the two
treatment arms. The failure to demonstrate a decrease
in blood vessel density in the combination arm may be
explained by either a true lack of benefit or by a limita-
tion of the methodology employed. Other studies of
anti-angiogenic agents in advanced HCC have examined
vessel permeability, and tumor blood volume and blood
Table 3 Comparison of observed bevacizumab serum concentrations (unit: μg/mL) in the current study to predicted
data
Mean Concentration (95% Confidence Interval)
Time Day 1 Day 15 Day 29 Day 43 Day 57 Day 85
Peak Study Subjects 203
(181-225)
237
(211-263)
297
(268-325)
280
(232-328)
272
(231-313)
333
(300-366)
Predicted from PopPK 256
(147-405)
317
(172-497)
356
(196-569)
378
(212-616)
392
(212-628)
404
(207-664)
Trough Study Subjects N/A
a 35.4
(31.5-39.4)
74.3
(66.7-82.0)
84.7
(60.4-109)
97.7
(71.3-124)
119
(95.4-142)
Predicted from PopPK N/A 58.2
(23.6-103)
95.6
(43.1-171)
122
(50.9-232)
139
(51.3-270)
156
(60.0-323)
Time Day 8 Day 11
Other Study Subjects 83.2
(71.7-94.6)
60.9
(53.2-68.6)
Predicted from PopPK 78.8
(34.4-138)
67.8
(27.9-123)
a N/A is ‘not applicable’.
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Figure 6 Effect of TACE on serum VEGF levels. Fold-change in VEGF levels over time are depicted for observation and bevacizumab arms.
One-sided t-test values for each timepoint are as follows: 1 h, 0.053; 24 h, 0.167; 48 h, 0.161; 72 h, 0.048; 360 h, 0.039; 528 h, 0.063; 696 h, 0.06
Britten et al. BMC Cancer 2012, 12:16
http://www.biomedcentral.com/1471-2407/12/16
Page 10 of 13flow using dynamic contrast enhanced MRI (DCE-MRI)
or perfusion CT [22,23]. In recent years, there has been
an increasing interest in the use of these techniques as
surrogates of microvessel density as measured by immu-
nohistochemistry [24], and there is an ongoing effort to
incorporate in vivo assessments of tumor angiogenesis
into clinical trials of anti-angiogenic agents.
The statistically significant improvement in PFS
observed in the TACE-BEV arm is interpreted with cau-
tion, due to the small sample size. Progression was
taken as any new sign of tumor activity, including neo-
vascularity on angiogram, new enhancement of an exist-
ing lesion by CT or MRI, or development of a new
lesion, according to institutional practice. There was a
low threshold for determining progressive disease,
because TACE was often used as a bridge to transplant,
and earlier treatment could potentially prevent subjects
from becoming ineligible for transplant due to tumor
volume. The modified Response Evaluation Criteria in
Solid Tumors (mRECIST) criteria for hepatocellular
cancer, in which disease assessments are based on the
sum of the diameters of viable disease rather than on
the sum of the total diameters of the target lesions,
were published after this study had begun [25]. The
mRECIST criteria were not applied retrospectively
because the majority of subjects on this trial were
imaged with CT rather than MRI, and ethiodol used
during TACE obscured the CT findings of
enhancement.
There was no statistically significant difference in
overall survival between the two treatment arms, with a
median survival of 49 months for the TACE-BEV arm,
and 61 months for the TACE-O arm. Beyond 36
months, the ability to estimate the survival curves with
any precision is impaired due to small sample size and
wide confidence intervals. Analysis of overall survival is
further hampered by the cross-over design. Any per-
ceived difference in overall survival cannot be attributed
to bevacizumab toxicity, because there were no bevaci-
zumab-related deaths, and all subjects succumbed to
underlying disease. As a whole, the striking overall sur-
vival rates in this pilot study are undoubtedly due to the
fact that 12 of the 30 subjects enrolled were ultimately
transplanted.
At the initiation of this trial, there was no prior
experience with bevacizumab in HCC, and there were
concerns regarding the safety of bevacizumab in subjects
with an increased risk of bleeding. Several layers of pro-
tection were built into the study to address this issue,
including a minimum platelet count of 60 to 100,000/μL
(depending on the time of enrolment), mandatory endo-
scopy for any subject with a prior history of grade III
varices or gastrointestinal bleeding, and careful follow-
up. During the core phase, none of the 15 TACE-BEV
subjects developed gastrointestinal bleeding, while one
TACE-O subject experienced grade 3 variceal bleeding.
During the continuation phase, 3 of the 13 (9 TACE-
BEV and 4 cross-over) subjects who received bevacizu-
mab developed grade 2/3 treatment-related gastrointest-
inal bleeding, but no episode was life-threatening. In
addition, while every effort was made to prevent subjects
from receiving bevacizumab at the time of OLT, one
subject was transplanted 9 days after his last dose of
bevacizumab, fortunately without incident. This experi-
ence is difficult to directly compare with the contem-
poraneous phase II trial of single-agent bevacizumab in
advanced HCC that reported an 11% incidence of ser-
ious bleeding, including one fatal event, because the
advanced HCC study included a higher proportion of
Child’s class B subjects [26]. As the field moves forward
with the evaluation of anti-angiogenic agents in early
stage HCC, caution regarding the risk of bleeding and
the potential for decreased wound healing in this special
population is advised.
The PK parameters for bevacizumab observed in the
small number of subjects (n = 15) were within the range
expected for oncology subjects in general. The popula-
tion PK model of bevacizumab was based on a heteroge-
neous population that included subjects with liver
metastasis, yet liver function enzymes (e.g., alkaline
phosphatase and serum glutamic oxaloacetic transami-
nase) were not covariates that significantly influenced
bevacizumab PK. These clinical findings are substan-
tiated by a preclinical study in rats in which hepatic dys-
function induced by bile duct ligation did not alter the
exposure (AUC0 - 11) of bevacizumab following a single
20 mg/kg IV bolus injection [27]. Overall, based on
these findings, well-compensated subjects with hepato-
cellular carcinoma are expected to have predictable bev-
acizumab disposition.
Serum VEGF levels increased after TACE in both
study arms, as described in previous studies [10,12,17],
but the administration of bevacizumab appeared to miti-
gate this effect. These results demonstrate that post-
TACE VEGF levels can be modulated by bevacizumab,
thereby reducing the ability of TACE to stimulate
VEGF-mediated angiogenesis.
In summary, this study demonstrates that TACE com-
bined with bevacizumab is safe and feasible in carefully-
selected subjects with HCC. The size of the study limits
any strong conclusions regarding efficacy, and ultimately
a large randomized study would be required to deter-
mine if there is an improvement in outcome with the
addition of bevaczicumab over TACE alone. Since this
study was first designed and implemented, there have
been many advances in the field, including confirmation
of proof of principal for anti-angiogenic agents in
advanced HCC [21], incorporation of novel imaging
Britten et al. BMC Cancer 2012, 12:16
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Page 11 of 13modalities to monitor angiogenesis in vivo [24], adapta-
tion of standardized response criteria in HCC [25], and
the development of doxorubicin-impregnated beads for
TACE [28]. Larger ongoing studies with agents such as
sorafenib and brivanib will help clarify the role of sys-
temic anti-angiogenic agents as an adjunct to TACE.
This pilot study, though limited by the state of the art
at its inception, provides further support for this
approach.
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